Finding the needle in the haystack

Rassier, Sarah L. Cohen; Stewart, Elizabeth A.

doi:10.1016/j.fertnstert.2020.09.146

Cited by 1 publication

(1 citation statement)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The use of these tests in combination with patient demographics, such as age and menopausal status, has been proposed for use independently or as part of an algorithm to determine a "preoperative risk score" for uterine tumors [7,[21][22][23]. Although some of these evaluative tools show promise, their reported testing properties must be interpreted cautiously based on the generalizability of the studies to the population at large [24]. Thus, despite the progress made so far, the preoperative diagnosis of LMS remains a challenge, and improving accurate diagnosis through novel and innovative approaches remains a critical and unmet need.…”

Section: Challenges With Differentiating Uterine Leiomyoma From Uteri...mentioning

confidence: 99%

Comprehensive Review of Uterine Leiomyosarcoma: Pathogenesis, Diagnosis, Prognosis, and Targeted Therapy

Yang,

Madueke-Laveaux,

Cun

et al. 2024

Cells

View full text Add to dashboard Cite

Uterine leiomyosarcoma (uLMS) is the most common subtype of uterine sarcomas. They have a poor prognosis with high rates of recurrence and metastasis. The five-year survival for uLMS patients is between 25 and 76%, with survival rates approaching 10–15% for patients with metastatic disease at the initial diagnosis. Accumulating evidence suggests that several biological pathways are involved in uLMS pathogenesis. Notably, drugs that block abnormal functions of these pathways remarkably improve survival in uLMS patients. However, due to chemotherapy resistance, there remains a need for novel drugs that can target these pathways effectively. In this review article, we provide an overview of the recent progress in ascertaining the biological functions and regulatory mechanisms in uLMS from the perspective of aberrant biological pathways, including DNA repair, immune checkpoint blockade, protein kinase and intracellular signaling pathways, and the hedgehog pathway. We review the emerging role of epigenetics and epitranscriptome in the pathogenesis of uLMS. In addition, we discuss serum markers, artificial intelligence (AI) combined with machine learning, shear wave elastography, current management and medical treatment options, and ongoing clinical trials for patients with uLMS. Comprehensive, integrated, and deeper insights into the pathobiology and underlying molecular mechanisms of uLMS will help develop novel strategies to treat patients with this aggressive tumor.

show abstract